Comparison of Residual Cancer Burden, American Joint Committee on Cancer staging and Pathologic Complete Response in Breast Cancer after Neoadjuvant Chemotherapy: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

PURPOSE: Several pathologic staging systems characterize residual tumor in patients undergoing neoadjuvant chemotherapy for breast cancer. Pathologic complete response (pCR) is now accepted by the Food and Drug Administration as an endpoint for granting accelerated drug approval. Two other systems o...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Breast Cancer Res Treat
Glavni autori: Campbell, Jeffrey I., Yau, Christina, Krass, Polina, Moore, Dan, Carey, Lisa A., Au, Alfred, Chhieng, David, Giri, Dilip, Livasy, Chad, Mies, Carolyn, Rabban, Joseph, Sarode, Venetia R., Singh, Baljit, Esserman, Laura, Chen, Yunn-Yi
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5653207/
https://ncbi.nlm.nih.gov/pubmed/28577078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4303-8
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items